Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18

Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71

Targeting metabolic transformation for cancer therapy. Nat Rev Cancer (2010) 5.90

The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer (2012) 4.72

Targeting the mTOR signaling network for cancer therapy. J Clin Oncol (2009) 4.52

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08

Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04

Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86

Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68

G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov (2011) 3.31

Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) (2011) 2.77

Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) (2010) 2.60

Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res (2011) 2.53

Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control (2009) 2.49

Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res (2009) 2.36

Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget (2011) 2.28

mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab (2011) 2.28

Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 2.28

Amino acid signaling to mTOR mediated by inositol polyphosphate multikinase. Cell Metab (2011) 2.24

Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest (2013) 2.14

AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11

Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11

Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00

Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal (2008) 1.96

Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet (2008) 1.96

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med (2011) 1.93

Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) (2012) 1.90

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol (2009) 1.78

Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res (2010) 1.76

LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Metab (2009) 1.70

Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res (2010) 1.70

Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep (2012) 1.66

Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev (2011) 1.65

Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila) (2010) 1.62

Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci U S A (2014) 1.62

mTOR: a pharmacologic target for autophagy regulation. J Clin Invest (2015) 1.61

Peutz-Jeghers syndrome: diagnostic and therapeutic approach. World J Gastroenterol (2009) 1.57

Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer (2014) 1.55

Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol (2014) 1.51

Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer (2011) 1.48

Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A (2010) 1.46

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol (2011) 1.45

Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther (2011) 1.43

Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci U S A (2012) 1.43

Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res (2011) 1.43

NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget (2011) 1.42

Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun (2012) 1.41

Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis (2012) 1.41

Metformin exhibits preventive and therapeutic efficacy against experimental cystic echinococcosis. PLoS Negl Trop Dis (2017) 1.40

Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer (2013) 1.39

Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer (2009) 1.38

Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene (2009) 1.34

Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist (2013) 1.32

Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY) (2012) 1.31

The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta (2010) 1.29

Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes (2009) 1.28

AMPK at the nexus of energetics and aging. Cell Metab (2014) 1.28

Dietary interventions to extend life span and health span based on calorie restriction. J Gerontol A Biol Sci Med Sci (2010) 1.23

Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res Treat (2009) 1.23

Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med (2012) 1.22

Coming of age: molecular drivers of aging and therapeutic opportunities. J Clin Invest (2013) 1.22

Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol (2012) 1.21

Autophagy modulation for cancer therapy. Cancer Biol Ther (2011) 1.20

Metformin in cancer prevention and therapy. Ann Transl Med (2014) 1.18

Anticancer agents that counteract tumor glycolysis. ChemMedChem (2012) 1.17

Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care (2013) 1.15

Regulation of mRNA translation by signaling pathways. Cold Spring Harb Perspect Biol (2012) 1.13

The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer (2008) 1.12

Targeting the metabolic microenvironment of tumors. Adv Pharmacol (2012) 1.11

Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab (2013) 1.11

Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. Oncotarget (2012) 1.11

Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One (2014) 1.10

Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res (Phila) (2012) 1.10

Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem (2011) 1.10

Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila) (2013) 1.08

Gerosuppressant metformin: less is more. Aging (Albany NY) (2011) 1.08

Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol (2013) 1.06

The role of mTOR signaling in Alzheimer disease. Front Biosci (Schol Ed) (2012) 1.05

Biology of obesity: lessons from animal models of obesity. J Biomed Biotechnol (2011) 1.05

Risk of cancer in diabetes: the effect of metformin. ISRN Endocrinol (2013) 1.04

Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle (2012) 1.03

Cordycepin inhibits protein synthesis and cell adhesion through effects on signal transduction. J Biol Chem (2009) 1.03

Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol (2010) 1.02

La-related protein 4 binds poly(A), interacts with the poly(A)-binding protein MLLE domain via a variant PAM2w motif, and can promote mRNA stability. Mol Cell Biol (2010) 1.02

Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis. PLoS Biol (2015) 1.02

Energy disruptors: rising stars in anticancer therapy? Oncogenesis (2016) 1.02

Gene expression module-based chemical function similarity search. Nucleic Acids Res (2008) 1.01

Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat (2011) 1.01

Macrophage autophagy in atherosclerosis. Mediators Inflamm (2013) 1.00

Synergistic anti-cancer effect of phenformin and oxamate. PLoS One (2014) 0.99

Age-related impairment of pancreatic Beta-cell function: pathophysiological and cellular mechanisms. Front Endocrinol (Lausanne) (2014) 0.99

AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma. PLoS One (2014) 0.98

New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 0.98

Leucine signaling in the pathogenesis of type 2 diabetes and obesity. World J Diabetes (2012) 0.98

Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer. Aging Cell (2016) 0.98

Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Ann Transl Med (2014) 0.97

Suppression of the HSF1-mediated proteotoxic stress response by the metabolic stress sensor AMPK. EMBO J (2014) 0.97

Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol Oncol (2012) 0.97

Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci (2012) 0.96

Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer. Trends Pharmacol Sci (2015) 0.96

Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet (2008) 32.08

Upstream and downstream of mTOR. Genes Dev (2004) 21.61

Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem (2010) 12.06

Translational control in stress and apoptosis. Nat Rev Mol Cell Biol (2005) 8.91

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99

XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity (2004) 6.72

Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71

Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature (2005) 6.69

mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 4.81

Translational control of long-lasting synaptic plasticity and memory. Neuron (2009) 4.77

Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol Cell (2009) 4.57

RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem (2007) 4.45

MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science (2007) 4.33

A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A (2001) 4.16

Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol (2002) 4.11

Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell (2010) 4.01

Diabetes and cancer: a consensus report. CA Cancer J Clin (2010) 3.95

Mammalian poly(A)-binding protein is a eukaryotic translation initiation factor, which acts via multiple mechanisms. Genes Dev (2005) 3.92

The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol (2003) 3.90

eIF4E--from translation to transformation. Oncogene (2004) 3.78

Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2. Nature (2010) 3.77

Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem (2005) 3.74

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62

The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J (2006) 3.57

eIF2alpha phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell (2007) 3.46

The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol (2012) 3.42

The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem (2004) 3.31

Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J (2004) 3.29

Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature (2012) 3.13

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13

The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell (2008) 3.10

Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst (2002) 3.03

Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol (2004) 3.00

14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature (2007) 2.98

Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell (2004) 2.91

Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta (2009) 2.89

Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest (2007) 2.86

Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat Cell Biol (2005) 2.80

A new paradigm for translational control: inhibition via 5'-3' mRNA tethering by Bicoid and the eIF4E cognate 4EHP. Cell (2005) 2.80

The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74

The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res (2008) 2.70

Metformin improves healthspan and lifespan in mice. Nat Commun (2013) 2.68

Translational control of hippocampal synaptic plasticity and memory by the eIF2alpha kinase GCN2. Nature (2005) 2.67

miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT. Nat Struct Mol Biol (2011) 2.61

Topology and regulation of the human eIF4A/4G/4H helicase complex in translation initiation. Cell (2009) 2.60

Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer (2008) 2.53

Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5' cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins. J Mol Biol (2002) 2.53

Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol (2010) 2.52

A role for the eIF4E-binding protein 4E-T in P-body formation and mRNA decay. J Cell Biol (2005) 2.51

A novel role of the mammalian GSPT/eRF3 associating with poly(A)-binding protein in Cap/Poly(A)-dependent translation. J Biol Chem (2002) 2.43

mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol (2011) 2.41

Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J (2006) 2.41

A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol Cell Biol (2004) 2.38

eIF4AIII binds spliced mRNA in the exon junction complex and is essential for nonsense-mediated decay. Nat Struct Mol Biol (2004) 2.38

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res (2008) 2.37

Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One (2007) 2.35

Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33

The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus. J Neurosci (2005) 2.33

Translational control of the innate immune response through IRF-7. Nature (2008) 2.30

Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev (2005) 2.28

Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science (2002) 2.28

Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J (2007) 2.27

Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev (2003) 2.26

The dynamics of mammalian P body transport, assembly, and disassembly in vivo. Mol Biol Cell (2008) 2.25

Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ (2005) 2.24

The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) (2008) 2.23

A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst (2004) 2.22

Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol Cell (2012) 2.19

The Akt of translational control. Oncogene (2005) 2.15

Cap and cap-binding proteins in the control of gene expression. Wiley Interdiscip Rev RNA (2010) 2.11

Reconstitution reveals the functional core of mammalian eIF3. EMBO J (2007) 2.06

Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression. J Neurosci (2006) 2.04

MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest (2010) 2.04

Activation of GCN2 in UV-irradiated cells inhibits translation. Curr Biol (2002) 2.02

Leishmania repression of host translation through mTOR cleavage is required for parasite survival and infection. Cell Host Microbe (2011) 2.01

Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet (2011) 2.00

Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc Natl Acad Sci U S A (2005) 2.00

Two structurally atypical HEAT domains in the C-terminal portion of human eIF4G support binding to eIF4A and Mnk1. Structure (2006) 1.99

Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation. Mol Cell Biol (2005) 1.99

A nuclear translation-like factor eIF4AIII is recruited to the mRNA during splicing and functions in nonsense-mediated decay. Proc Natl Acad Sci U S A (2004) 1.97

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer (2008) 1.96

A novel, evolutionarily conserved protein phosphatase complex involved in cisplatin sensitivity. Mol Cell Proteomics (2005) 1.95

Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol Cell Biol (2006) 1.93

Phosphorylation of eukaryotic translation initiation factor 4E is critical for growth. Mol Cell Biol (2002) 1.92

mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab (2013) 1.91

Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene (2005) 1.89

La autoantigen is necessary for optimal function of the poliovirus and hepatitis C virus internal ribosome entry site in vivo and in vitro. Mol Cell Biol (2004) 1.87

Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife (2013) 1.85

Starvation and oxidative stress resistance in Drosophila are mediated through the eIF4E-binding protein, d4E-BP. Genes Dev (2005) 1.84

Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr (2008) 1.80

Antiviral effect of the mammalian translation initiation factor 2alpha kinase GCN2 against RNA viruses. EMBO J (2006) 1.79

Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell (2012) 1.79

High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat (2008) 1.78

Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res (2008) 1.76

S6K1 plays a critical role in early adipocyte differentiation. Dev Cell (2010) 1.74